JP2010536858A - エリスロポエチン受容体ペプチド製剤及び用途 - Google Patents

エリスロポエチン受容体ペプチド製剤及び用途 Download PDF

Info

Publication number
JP2010536858A
JP2010536858A JP2010521913A JP2010521913A JP2010536858A JP 2010536858 A JP2010536858 A JP 2010536858A JP 2010521913 A JP2010521913 A JP 2010521913A JP 2010521913 A JP2010521913 A JP 2010521913A JP 2010536858 A JP2010536858 A JP 2010536858A
Authority
JP
Japan
Prior art keywords
peptide
epo
dose
peg
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010521913A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010536858A5 (enExample
Inventor
ドゥリエゲ，アニー‐マリー
ステッド，リチャード
レウザー，ケルスティン
ウッドバーン，キャスリン，ウィン
ナソ，ロバート，バーネット
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affymax Inc
Original Assignee
Affymax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affymax Inc filed Critical Affymax Inc
Publication of JP2010536858A publication Critical patent/JP2010536858A/ja
Publication of JP2010536858A5 publication Critical patent/JP2010536858A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2010521913A 2007-08-22 2008-07-23 エリスロポエチン受容体ペプチド製剤及び用途 Pending JP2010536858A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95739607P 2007-08-22 2007-08-22
US98975807P 2007-11-21 2007-11-21
PCT/US2008/070943 WO2009025958A1 (en) 2007-08-22 2008-07-23 Erythropoietin rceptor peptide formulations and uses

Publications (2)

Publication Number Publication Date
JP2010536858A true JP2010536858A (ja) 2010-12-02
JP2010536858A5 JP2010536858A5 (enExample) 2011-10-20

Family

ID=40194013

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010521913A Pending JP2010536858A (ja) 2007-08-22 2008-07-23 エリスロポエチン受容体ペプチド製剤及び用途
JP2010521912A Pending JP2010536857A (ja) 2007-08-22 2008-07-23 エリスロポエチン受容体ペプチドの製剤及び使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010521912A Pending JP2010536857A (ja) 2007-08-22 2008-07-23 エリスロポエチン受容体ペプチドの製剤及び使用

Country Status (3)

Country Link
EP (1) EP2195002A4 (enExample)
JP (2) JP2010536858A (enExample)
WO (2) WO2009025958A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9422338B2 (en) 2011-05-19 2016-08-23 Epodose Llc Compounds that bind to the erythropoietin receptor
WO2015183545A1 (en) * 2014-05-28 2015-12-03 The Board Of Regents Of The University Of Texas System Novel compounds supports hematopoietic stem cells and red blood cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004101606A2 (en) * 2003-05-12 2004-11-25 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
WO2006133144A2 (en) * 2005-06-03 2006-12-14 Affymax, Inc. Erythropoietin receptor peptide formulations and uses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ543935A (en) * 2003-05-12 2008-06-30 Affymax Inc Peptides that bind to the erythropoietin receptor
US7919461B2 (en) * 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US8343953B2 (en) * 2005-06-22 2013-01-01 Astex Therapeutics Limited Pharmaceutical compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004101606A2 (en) * 2003-05-12 2004-11-25 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
WO2006133144A2 (en) * 2005-06-03 2006-12-14 Affymax, Inc. Erythropoietin receptor peptide formulations and uses

Also Published As

Publication number Publication date
JP2010536857A (ja) 2010-12-02
WO2009025958A1 (en) 2009-02-26
WO2009025957A1 (en) 2009-02-26
EP2195002A4 (en) 2011-09-07
EP2195002A1 (en) 2010-06-16

Similar Documents

Publication Publication Date Title
JP4266028B2 (ja) エリスロポエチン受容体に結合する新規ペプチド
JP4949844B2 (ja) エリスロポエチン受容体に結合する新規ペプチド
KR101262312B1 (ko) 에리스로포이에틴 수용체 펩티드 포뮬레이션 및 용도
US7919461B2 (en) Erythropoietin receptor peptide formulations and uses
JP2010536858A (ja) エリスロポエチン受容体ペプチド製剤及び用途
US8324159B2 (en) Erythropoietin receptor peptide formulations and uses
JP2008519858A (ja) エリスロポエチンレセプターに結合する新規ペプチド
AU2012203812A1 (en) Erythropoietin receptor peptide formulations and uses
JP2009191056A (ja) 合成ペプチドをベースとするｅｐｏレセプターアゴニストを用いた抗エリスロポエチン抗体に媒介された障害の治療
HK1088906B (en) Peptides that bind to the erythropoietin receptor

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110901

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130226

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130521

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130528

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130617

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130725

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140401

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140924